Impact of BMI on A1c Reduction in Response to IDegLira in Subjects with Type 2 Diabetes (T2D) Uncontrolled on SU, GLP-1RA, or Insulin Glargine: Analyses from Completed Phase 3b Trials

被引：0
|
作者：
Harris, Stewart B.
Jaeckel, Elmar
Jodar, Esteban
Lingvay, Ildiko
Chandarana, Keval
Abrahamsen, Trine J.
Sorli, Christopher H.
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
938-P
引用
收藏
页码：A242 / A242
页数：1
相关论文
共 50 条
  • [1] IDegLira Is Efficacious across Baseline A1c Categories in Subjects with Type 2 Diabetes Uncontrolled on SU, GLP-1RA, or Insulin Glargine: Analyses from Completed Phase 3b Trials
    Sorli, Christopher H.
    Harris, Stewart B.
    Jodar, Esteban
    Lingvay, Ildiko
    Chandarana, Keval
    Langer, Jakob
    Jaeckel, Elmar
    DIABETES, 2016, 65 : A238 - A238
  • [2] Impact of BMI on HbA1c reduction in response to IDegLira in subjects with type 2 diabetes uncontrolled on SU, GLP-IRA or IGlar U100: analyses from completed phase 3b trials
    Jodar, E.
    Harris, S. B.
    Jaeckel, E.
    Lingvay, I.
    Chandarana, K.
    Abrahamsen, T.
    Sorli, C. H.
    DIABETOLOGIA, 2016, 59 : S401 - S402
  • [3] IDegLira is efficacious across baseline HbA1c categories in subjects with type 2 diabetes uncontrolled on SU, GLP-1RA or IGlar U100: analyses from completed phase 3b trials
    Jaeckel, E.
    Harris, S. B.
    Jodar, E.
    Lingvay, I.
    Chandarana, K.
    Langer, J.
    Sorli, C. H.
    DIABETOLOGIA, 2016, 59 : S401 - S401
  • [4] Impact of BMI on HbA1c Reduction, Hypoglycemia Rates, and Insulin Requirements in Response to IDegLira in Patients with Type 2 Diabetes (T2D)
    Buse, John B.
    Rodbard, Helena W.
    Woo, Vincent C.
    Vilsboll, Tina
    La Bandier, Micha
    Korsholm, Lars
    Gough, Stephen
    DIABETES, 2014, 63 : A18 - A18
  • [5] IDegLira is efficacious across baseline HbA1c categories in subjects with Type 2 diabetes uncontrolled on sulphonylurea, glucagon-like peptide-1 receptor agonist or insulin glargine U100: analyses from completed phase 3b trials
    Viljoen, A.
    Sorli, C. H.
    Harris, S.
    Jodar, E.
    Lingvay, I.
    Chandarana, K.
    Langer, J.
    Jaeckel, E.
    DIABETIC MEDICINE, 2017, 34 : 163 - 163
  • [6] Efficacy and Safety of IDegLira (Combination of Insulin Degludec plus Liraglutide), in Insulin-Naive Patients with T2D Uncontrolled on GLP-1 Receptor Agonist (GLP-1RA) Therapy
    Linjawi, Sultan
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jean-Pierre
    Handelsman, Yehuda
    Lehmann, Lucine
    Mishra, Abhishek
    Simpson, Richard W.
    DIABETES, 2015, 64 : A255 - A255
  • [7] Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%-Analyses from the DUAL Program
    Sugimoto, Danny
    Frias, Juan P.
    Gouet, Didier
    Takacs, Robert
    Jia, Ting
    Orsy, Petra
    Bain, Stephen C.
    DIABETES, 2018, 67
  • [8] Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
    Lisco, Giuseppe
    De Tullio, Anna
    Disoteo, Olga
    De Geronimo, Vincenzo
    Piazzolla, Giuseppina
    De Pergola, Giovanni
    Giagulli, Vito Angelo
    Jirillo, Emilio
    Guastamacchia, Edoardo
    Sabba, Carlo
    Triggiani, Vincenzo
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [9] Efficacy and safety of IDegLira (combination of insulin degludec plus liraglutide), in insulin-naive patients with type 2 diabetes uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. -P.
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETOLOGIA, 2015, 58 : S401 - S402
  • [10] Real-World Adherence and Discontinuation of GLP-1 Receptor Agonist (GLP-1RA) Therapy in Type 2 Diabetes (T2D) Patients in the US
    Weiss, Tracey
    Iglay, Kristy
    Carr, Richard D.
    Mishra, Ajay Pratap
    Yang, Lingfeng
    Rajpathak, Swapnil
    DIABETES, 2019, 68
12345